Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Le virus de l’herpès simplex, que ce soit le simplex 1 (HSV- 1) ou le simplex 2 (HSV-2) est véritablement un fléau mondial. On estimait, en 2012, que 67% de la population internationale infectée par le HSV-1 et que 417 millions de personnes portaient le HSV-2. Ces virus sont responsables dans la plupart des cas de lésions désagréables au niveau du visage et des parties génitales, mais dans certains cas provoquent des complications graves telles qu'une encéphalite ou méningite et un herpès néonatal parfois pour le nourrisson. Les traitements actuels sontmais consistent seulement à atténuer les symptômes lors d'une primo-infection ou récurrence. C'est pourquoi les firmes pharmaceutiques sont à la recherche d’une recherche s’est concentrée en premier sur l'approche prophylactique, mais les résultats des études très décevants. Suite à ces résultats, les firmes pharmaceutiques se focalisent aujourd'hui sur un vaccin thérapeutique afin de diminuer la sévérité et la fréquence des épisodes de et excrétions virales. Nous allons découvrir quelles ont été les raisons possibles de l'échec du vaccin prophylactique, l'avancement de la recherche etdéveloppement vaccin thérapeutique pour finalement tenter de répondre à la question suivante : le vaccin thérapeutique pourrait-il son épingle du jeu ? The virus herpes simplex 1 (HSV-1) or simplex 2 (HSV-2) are a worldwide scourge. In 2012, it was estimated that 67% of the international population was infected by HSV-1 and 417 million people were living with HSV-2. In general, those viruses are responsible for unpleasant facials and genitals lesions. In some cases, they cause serious complications such as encephalitis or meningitis and neonatal herpes, which can be fatal for the new born. The current treatments are effective but they only attenuate the symptoms during a primary infection or viral recurrence. It is why pharmaceutical companies are looking for a vaccine. The research primarily focused on the prophylactic approach but the results of the studies were very disappointing. Following these results, pharmaceutical companies are now focusing on a therapeutic vaccine to reduce the severity and frequency of recurrence episodes and viral shedding. We will discover which are the possible reasons for the failure of the prophylactic vaccine and the advancement of research and development of the therapeutic vaccine. We will try to finally answer the following question: the therapeutic vaccine will be able to emerge?

Herpes Simplex Virus Vaccines --- Antibiotic Prophylaxis --- Vaccination

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Influenza vaccines --- Nervous system --- Influenza virus vaccines --- Viral vaccines --- Neuroimmunology --- Side effects. --- Diseases --- Immunological aspects.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines. Fortunately, a quantum leap in technology has revolutionized the study of influenza and the engineering of new vaccine strains by reverse genetics. This volume provides a historical background and state-of-the-art information about the recent advances in the biology of influenza and the design of new influenza vaccines.

Influenza vaccines. --- Influenza. --- Influenza viruses. --- Orthomyxoviruses --- Flu --- Flu, Respiratory --- Grippe --- Respiratory flu --- Respiratory infections --- Virus diseases --- Influenza virus vaccines --- Viral vaccines --- Medical virology. --- Life sciences. --- Virology. --- Life Sciences, general. --- Biosciences --- Sciences, Life --- Science --- Medical microbiology --- Virology --- Microbiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Influenza vaccines. --- Influenza viruses. --- Influenza. --- Influenza --- Influenza vaccines --- Influenza viruses --- Orthomyxoviruses --- Influenza virus vaccines --- Viral vaccines --- Flu --- Flu, Respiratory --- Grippe --- Respiratory flu --- Respiratory infections --- Virus diseases --- INFLUENZAVIRUS A --- RNA VIRUSES --- INFLUENZA, HUMAN --- INFLUENZA VACCINES --- METABOLISM --- IMMUNOLOGY --- PATHOGENICITY --- HISTORY

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antigens, Viral --- Viral Vaccines --- Virus Diseases --- Viral vaccines --- Antiviral agents --- Virus diseases --- Vaccins antiviraux --- Antiviraux --- Maladies à virus --- immunology. --- therapeutic use. --- prevention & control. --- Chemotherapy --- Chimiothérapie --- Virus vaccines --- Vaccines --- Antiviral drugs --- Antivirals --- Anti-infective agents --- Virus inhibitors --- immunology --- therapeutic use --- prevention & control